Serena Jingchuan Guo

Serena Jingchuan Guo, M.D., Ph.D.

Assistant Professor

Department: Pharmaceutical Outcomes & Policy
Business Phone: (352) 273-6533
Business Email: guoj1@ufl.edu

About Serena Jingchuan Guo

Serena Guo is Assistant Professor in the Department of Pharmaceutical Outcomes and Policy at the University of Florida (UF) College of Pharmacy. She received her MD from Peking University in Beijing, China and her PhD in Epidemiology from the University of Pittsburgh. After a one-year postdoctoral fellowship in the Center for Pharmaceutical Policy and Prescribing also at the University of Pittsburgh, in December 2020, Dr. Guo joined the faculty of UF.

Dr. Guo conducts research in pharmacoepidemiology and pharmacoinformatics, primarily focused on cardiometabolic diseases and neurodegenerative conditions (e.g., dementia) with the goals of promoting precision health and health equity. Her research draws on large real-world data (e.g., electronic health records and insurance claims data) and advanced analytics (e.g., AI/machine learning, causal-principled modeling, and geospatial analyses) to: 1) assess comparative effectiveness/safety and heterogeneous treatment effects (HTEs) of treatments and interventions, and 2) develop individualized and intelligent social risk management tools to be integrated into clinical care. Dr. Guo has published over 90 peer-reviewed manuscripts. Several articles have been published in top-tier journals, including Diabetes Care, Lancet and BMJ, and featured in media outlets, including Washington Post, NPR, and CNN. Her research programs and collaborations have been funded by the NIH, Veterans Affairs, CDC, FDA and the PhRMA Foundation.

Related Links:

Accomplishments

Assistant Professor Award of Excellence
2024 · University of Florida
JMCP Award for Excellence
2023 · Academy of Managed Care Pharmacy

Teaching Profile

Courses Taught
2021-2023
PHA6805 Applied Data Interpretation and Reporting of Findings in Pharmacy
2022-2025
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2022-2023
PHA5878C Pt Care 3: Cv and Pulm
2022-2023
PHA6938 Research Seminar
2023-2025
PHA6935 Selected Topics in Pharmacy
2023-2024
PHA5244 Prin Evid Based Prac
2023-2025
PHA7979 Advanced Research
2023-2025
PHA6971 Research for Master’s Thesis
2023
PHA6946 Practicum in the Pharmaceutical Sciences
2024-2025
PHA7980 Research for Doctoral Dissertation

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0001-9799-2592

Areas of Interest
  • Health disparities and Social determinants of health
  • Pharmacoepidemiology
  • Pharmacoinformatics

Publications

2024
5‐Year simulation of diabetes‐related complications in people treated with tirzepatide or semaglutide versus insulin glargine
Diabetes, Obesity and Metabolism. 26(2):463-472 [DOI] 10.1111/dom.15332. [PMID] 37867175.
2024
Association between low cognitive performance and diabetes‐related health indicators across racial and ethnic groups in adults with diabetes
Diabetes, Obesity and Metabolism. [DOI] 10.1111/dom.15715.
2024
Associations Between Postdischarge Care and Cognitive Impairment–Related Hospital Readmissions for Ketoacidosis and Severe Hypoglycemia in Adults With Diabetes
Diabetes Care. 47(2):225-232 [DOI] 10.2337/dca23-0013. [PMID] 38048487.
2024
Feasibility of Identifying Factors Related to Alzheimer’s Disease and Related Dementia in Real-World Data.
medRxiv : the preprint server for health sciences. [DOI] 10.1101/2024.02.10.24302621. [PMID] 38405723.
2024
Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes
PLOS ONE. 19(1) [DOI] 10.1371/journal.pone.0297208. [PMID] 38285682.
2024
Incremental burden on health‐related quality of life, health service utilization and direct medical expenditures associated with cognitive impairment among non‐institutionalized people with diabetes aged 65 years and older
Diabetes, Obesity and Metabolism. 26(1):275-282 [DOI] 10.1111/dom.15313.
2023
Association between Antidepressants and Dementia Risk in Older Adults with Depression: A Systematic Review and Meta-Analysis
Journal of Clinical Medicine. 12(19) [DOI] 10.3390/jcm12196342. [PMID] 37834986.
2023
Changes in racial and ethnic disparities in glucose‐lowering drug utilization and glycated haemoglobin A1c in US adults with diabetes: 2005‐2018
Diabetes, Obesity and Metabolism. 25(2):516-525 [DOI] 10.1111/dom.14894. [PMID] 36251173.
2023
COVID-19 pandemic and initiation of treatment for atrial fibrillation: a nationwide analysis of claims data
BMC Cardiovascular Disorders. 23(1) [DOI] 10.1186/s12872-023-03614-z. [PMID] 38066445.
2023
Enriching Real-world Data with Social Determinants of Health for Health Outcomes and Health Equity: Successes, Challenges, and Opportunities.
Yearbook of medical informatics. 32(1):253-263 [DOI] 10.1055/s-0043-1768732. [PMID] 38147867.
2023
Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose‐Lowering Drugs: A Meta‐Analysis of Randomized Outcome Trials
Journal of the American Heart Association. 12(10) [DOI] 10.1161/jaha.122.026791.
2023
Impact of Contextual-Level Social Determinants of Health on Newer Antidiabetic Drug Adoption in Patients with Type 2 Diabetes
International Journal of Environmental Research and Public Health. 20(5) [DOI] 10.3390/ijerph20054036. [PMID] 36901047.
2023
Meta‐analysis of Association between Newer Glucose‐Lowering Drugs and Risk of Parkinson’s Disease
Movement Disorders Clinical Practice. 10(11):1659-1665 [DOI] 10.1002/mdc3.13893. [PMID] 37982117.
2023
Newer glucose‐lowering drugs and risk of dementia: A systematic review and meta‐analysis of observational studies
Journal of the American Geriatrics Society. 71(7):2096-2106 [DOI] 10.1111/jgs.18306. [PMID] 36821780.
2022
Access to community pharmacies: A nationwide geographic information systems cross-sectional analysis
Journal of the American Pharmacists Association. 62(6):1816-1822.e2 [DOI] 10.1016/j.japh.2022.07.003.
2022
Are novel glucose‐lowering agents’ cardiorenal benefits generalizable to individuals of Black race? A meta‐trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment
Diabetes, Obesity and Metabolism. 24(1):154-159 [DOI] 10.1111/dom.14540.
2022
Changes in predicted opioid overdose risk over time in a state Medicaid program: a group‐based trajectory modeling analysis
Addiction. 117(8):2254-2263 [DOI] 10.1111/add.15878. [PMID] 35315173.
2022
Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials
Diabetes Care. 45(4):1007-1012 [DOI] 10.2337/dc21-1722.
2022
Disparities in distribution of COVID-19 vaccines across US counties: A geographic information system–based cross-sectional study
PLOS Medicine. 19(7) [DOI] 10.1371/journal.pmed.1004069. [PMID] 35901171.
2022
Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: group‐based multi‐trajectory models
Addiction. 117(7):1982-1997 [DOI] 10.1111/add.15857.
2022
Effect of the COVID-19 pandemic on adversity in individuals receiving anticoagulation for atrial fibrillation: A nationally representative administrative health claims analysis.
American heart journal plus : cardiology research and practice. 13 [DOI] 10.1016/j.ahjo.2022.100096. [PMID] 35136865.
2022
Growing global burden of type 1 diabetes needs multitiered precision public health interventions.
The lancet. Diabetes & endocrinology. 10(10):688-689 [DOI] 10.1016/S2213-8587(22)00257-1. [PMID] 36113506.
2022
Identifying Patients at Risk of Acute Kidney Injury Among Medicare Beneficiaries With Type 2 Diabetes Initiating SGLT2 Inhibitors: A Machine Learning Approach.
Frontiers in pharmacology. 13 [DOI] 10.3389/fphar.2022.834743. [PMID] 35359843.
2022
Income disparities in driving distance to health care infrastructure in the United States: a geographic information systems analysis
BMC Research Notes. 15(1) [DOI] 10.1186/s13104-022-06117-w. [PMID] 35761413.
2022
Newer glucose‐lowering drugs and risk of dementia: A meta‐analysis of cardiovascular outcome trials
Journal of the American Geriatrics Society. 70(9):2719-2722 [DOI] 10.1111/jgs.17895. [PMID] 35612586.
2022
Simulating Colorectal Cancer Trials Using Real-World Data
JCO Clinical Cancer Informatics. (6) [DOI] 10.1200/cci.21.00195.
2021
COVID-19 and Anticoagulation for Atrial Fibrillation: An Analysis of US Nationwide Pharmacy Claims Data.
Journal of the American Heart Association. 10(24) [DOI] 10.1161/JAHA.121.023235. [PMID] 34913359.
2021
Emerging treatments for lupus nephritis: health equity considerations in clinical research and coverage.
Journal of managed care & specialty pharmacy. 27(10):1500-1502 [DOI] 10.18553/jmcp.2021.27.10.1500. [PMID] 34595947.
2021
Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries
American Journal of Cardiovascular Drugs. [DOI] 10.1007/s40256-021-00475-9. [PMID] 33768423.
2021
Newer drug treatments for type 2 diabetes.
BMJ (Clinical research ed.). 373 [DOI] 10.1136/bmj.n1171. [PMID] 33975861.
2021
Predicting Mortality Risk After a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose.
Journal of general internal medicine. 36(4):908-915 [DOI] 10.1007/s11606-020-06405-w. [PMID] 33481168.
2021
Primary care provider payment models and adherence to anticoagulation in patients with atrial fibrillation.
Journal of managed care & specialty pharmacy. 27(12):1672-1679 [DOI] 10.18553/jmcp.2021.27.12.1672. [PMID] 34818086.
2021
Racial and Urban-Rural Difference in the Frequency of Ischemic Stroke as Initial Manifestation of Atrial Fibrillation.
Frontiers in public health. 9 [DOI] 10.3389/fpubh.2021.780185. [PMID] 34805085.
2021
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
Lancet (London, England). 396(10267):2019-2082 [DOI] 10.1016/S0140-6736(20)32374-6. [PMID] 33189186.
2021
Using machine learning to identify diabetes patients with canagliflozin prescriptions at high-risk of lower extremity amputation using real-world data.
Pharmacoepidemiology and drug safety. 30(5):644-651 [DOI] 10.1002/pds.5206. [PMID] 33606340.
2020
Comparison of Oral Anticoagulant Use and Stroke Risk Among Older Adults Newly-Diagnosed Atrial Fibrillation Living in Urban-Versus-Rural Areas.
The American journal of cardiology. 130:64-69 [DOI] 10.1016/j.amjcard.2020.06.015. [PMID] 32680675.
2020
Costs and outcomes of “intermediate” vs “minimal” care for youth-onset type 1 diabetes in six countries.
Pediatric diabetes. 21(4):628-636 [DOI] 10.1111/pedi.12988. [PMID] 31970828.
2020
Mediation analysis for estimating cardioprotection of longitudinal RAS inhibition beyond lowering blood pressure and albuminuria in type 1 diabetes.
Annals of epidemiology. 41:7-13.e1 [DOI] 10.1016/j.annepidem.2019.12.004. [PMID] 31928894.
2020
Occupational Patterns of Opioid-Related Overdose Deaths Among Arizona Medicaid Enrollees, 2008-2017.
Journal of general internal medicine. 35(7):2210-2213 [DOI] 10.1007/s11606-020-05684-7. [PMID] 32043261.
2019
Excess mortality and cardiovascular disease risk in type 1 diabetes.
Lancet (London, England). 393(10175) [DOI] 10.1016/S0140-6736(18)33047-2. [PMID] 30860050.
2019
Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen.
Journal of the American Society of Nephrology : JASN. 30(10):2000-2016 [DOI] 10.1681/ASN.2019030218.
2019
Greater progression of coronary artery calcification is associated with clinically relevant cognitive impairment in type 1 diabetes.
Atherosclerosis. 280:58-65 [DOI] 10.1016/j.atherosclerosis.2018.11.003. [PMID] 30471556.
2019
Optimal Blood Pressure Thresholds for Minimal Coronary Artery Disease Risk in Type 1 Diabetes.
Diabetes care. 42(9):1692-1699 [DOI] 10.2337/dc19-0480. [PMID] 31248910.
2019
Prognostic Significance of Pulse Pressure and Other Blood Pressure Components for Coronary Artery Disease in Type 1 Diabetes.
American journal of hypertension. 32(11):1075-1081 [DOI] 10.1093/ajh/hpz099. [PMID] 31214692.
2019
Serum long-chain n-3 polyunsaturated fatty acids and aortic calcification in middle-aged men: The population-based cross-sectional ERA-JUMP study.
Nutrition, metabolism, and cardiovascular diseases : NMCD. 29(8):837-846 [DOI] 10.1016/j.numecd.2019.04.011. [PMID] 31151884.
2019
The role of coronary artery calcification testing in incident coronary artery disease risk prediction in type 1 diabetes.
Diabetologia. 62(2):259-268 [DOI] 10.1007/s00125-018-4764-2. [PMID] 30426170.
2018
Association of alcohol consumption and aortic calcification in healthy men aged 40-49 years for the ERA JUMP Study.
Atherosclerosis. 268:84-91 [DOI] 10.1016/j.atherosclerosis.2017.11.017. [PMID] 29195109.
2018
Data on alcohol consumption and coronary artery calcification among asymptomatic middle-aged men for the ERA-JUMP study.
Data in brief. 17:1091-1098 [DOI] 10.1016/j.dib.2018.02.032. [PMID] 29876466.
2018
Left ventricular systolic dysfunction predicts long-term major microvascular complication outcomes in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications (EDC) study of childhood onset diabetes.
Journal of diabetes and its complications. 32(3):298-304 [DOI] 10.1016/j.jdiacomp.2017.12.004. [PMID] 29366734.
2017
Increased Aortic Calcification Is Associated With Arterial Stiffness Progression in Multiethnic Middle-Aged Men.
Hypertension (Dallas, Tex. : 1979). 69(1):102-108 [PMID] 27821619.
2017
Reply.
Journal of hypertension. 35(6):1326-1327 [DOI] 10.1097/HJH.0000000000001342. [PMID] 28441260.
2017
The role of initial and longitudinal change in blood pressure on progression of arterial stiffness among multiethnic middle-aged men.
Journal of hypertension. 35(1):111-117 [PMID] 27775956.
2016
Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.
British journal of clinical pharmacology. 82(2):352-61 [DOI] 10.1111/bcp.12950. [PMID] 27038001.

Grants

Jun 2024 ACTIVE
Semantics Standards and Tools for Spatial and Contextual Exposome Data
Role: Co-Investigator
Funding: NATL INST OF HLTH NIEHS
Sep 2023 ACTIVE
Newer Glucose-lowering drugs and risk of Alzheimer's disease and related dementia
Role: Other
Funding: PHARMA RES AND MANUFACTURERS OF AMERICA
Sep 2023 ACTIVE
Newer Glucose-Lowering Drugs and Risk of Parkinsons Disease in people with type 2 diabetes
Role: Other
Funding: AMER FOU FOR PHARM EDU
Jul 2023 ACTIVE
Together: Transforming and Translating Discovery to Improve Health
Role: Project Manager
Funding: NATL INST OF HLTH NCATS
Apr 2023 ACTIVE
Artificial Intelligence and Counterfactually Actionable Responses to End HIV (AICARE-HIV)
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Jan 2023 – Aug 2023
Medical Literature and Data on Cannabis Use
Role: Co-Investigator
Funding: HARVARD PILGRIM HEALTHCARE via US FOOD AND DRUG ADMN
Jan 2023 – Jul 2023
Supplement: The External Exposome and COVID-19 Severity among Individuals with Alzheimers Disease and Related Dementias
Role: Co-Investigator
Funding: BRIGHAM AND WOMENS HOSPITAL via NATL INST OF HLTH NIEHS
Dec 2022 ACTIVE
Assessing Barriers and Facilitators for Participating Structured Lifestyle Intervention
Role: Principal Investigator
Funding: EMORY UNIV via CTRS FOR DISEASE CONTROL AND PREVENTION
Oct 2022 – Sep 2023
VA IPA Year 1 Jingchuan Guo
Role: Principal Investigator
Funding: US DEPT OF VET AFF GAINESVILLE MED CTR
Sep 2022 ACTIVE
Patient-Focused Collaborative Hospital Repository Uniting Standards (CHoRUS) for Equitable AI
Role: Co-Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL via NATL INST OF HLTH OD
Sep 2022 – Dec 2022
Assessing Barriers and Facilitators for Participating Structured Lifestyle Intervention and Its Real-world Effectiveness and Cost-effectiveness among US Veterans
Role: Co-Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2022 ACTIVE
Building Equity Improvement into Quality Improvement in the use of New Glucose-lowering Drugs (GLDs) through Individualized Drug Value Assessment in People with Diabetes
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Jul 2022 ACTIVE
Machine-Learning Prediction and Reducing Overdoses with EHR Nudges (mPROVEN)
Role: Principal Investigator
Funding: UNIV OF PITTSBURGH via NATL INST OF HLTH NIDA
Jul 2022 – Jun 2024
Social Determinants Underlying Disparities in Heart Failure Treatment and Outcomes
Role: Principal Investigator
Funding: PHARMA RES AND MANUFACTURERS OF AMERICA
Dec 2021 – Jul 2023
The External Exposome and COVID-19 Severity and Mortality
Role: Co-Investigator
Funding: BRIGHAM AND WOMENS HOSPITAL via NATL INST OF HLTH NIEHS
Sep 2021 – Sep 2023
Disparities in Peripheral Arterial Disease Diagnosis and Treatment in Socioeconomically Disadvantaged Regions of Florida
Role: Other
Funding: AMER COL OF CARDIOLOGY
Jul 2021 ACTIVE
Pandemic Disruptions of Atrial Fibrillation Care
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN DIEGO via NATL INST OF HLTH NHLBI
Jul 2019 – Jun 2024
OoR Matching Support for CTSI
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS

Contact Details

Phones:
Business:
(352) 273-6533
Emails:
Business:
guoj1@ufl.edu
Addresses:
Business Mailing:
PO Box 100496
GAINESVILLE FL 32610
Business Street:
1889 Museum Road, DSIT 6004
Gainesville FL 32606